ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Degron Therapeutics has partnered with Takeda to develop molecular glue degraders that will be used in cancer, inflammation, and neuroscience treatments. The deal centers on Degron’s GlueXplorer platform, which will be used to identify possible degrader candidates. Separately, Monte Rosa Therapeutics, which also develops molecular glue degraders, says it has collected $100 million before expenses from its underwritten public offering. The company says its QuEEN platform uses AI, proteomics, drug libraries, and structural biology to identify candidates and targets.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X